Search

Displaying results 5931 - 5940 of 7017 in total
  1. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  2. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. … [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]

  3. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  4. Drug

    Ritobegron

    go.drugbank.com/drugs/DB12080
    Investigational

    Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male

  5. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency.

  6. Drug

    LJ-2698

    go.drugbank.com/drugs/DB18018
    Experimental

    Categories: Adenosine A3 Receptor Antagonists
  7. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). … It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.

  8. Drug

    Dexpemedolac

    go.drugbank.com/drugs/DB19987
    Experimental

    Dexpemedolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Dexpemedolac is a anti-inflammatory agent, ibufenac derivative. … Dexpemedolac has a monoisotopic molecular weight of 349.17 Da.

  9. Drug

    Isofezolac

    go.drugbank.com/drugs/DB20228
    Experimental

    Isofezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Isofezolac is a anti-inflammatory agent, ibufenac derivative. … Isofezolac has a monoisotopic molecular weight of 354.14 Da.

  10. Drug

    Clopirac

    go.drugbank.com/drugs/DB20824
    Experimental

    Clopirac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Clopirac is a anti-inflammatory agent, ibufenac derivative. … Clopirac has a monoisotopic molecular weight of 263.07 Da.